Antibacterial treatment of bacterial vaginosis: Current and emerging therapies

International Journal of Women's Health

Volumn 3, Issue 1, 2011, Pages 295-305

  Menard, Jean Pierre ^a  

^a Immeuble pyramide   (France)

Author keywords

Bacterial vaginosis; Emerging therapy; Treatment

Indexed keywords

2 PHENOXYETHANOL; ACETIC ACID; ANTIINFECTIVE AGENT; BORIC ACID; CLINDAMYCIN; DOXYCYCLINE; ESTRIOL; EUGENOL; GLYCEROL MONOLAURATE; METRONIDAZOLE; NIFURATEL; NYSTATIN; OCTENIDINE; PLACEBO; PREBIOTIC AGENT; PROBIOTIC AGENT; SECNIDAZOLE; THYMOL; TINIDAZOLE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; AMEBIASIS; ANAEROBIC INFECTION; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; ANTISEPSIS; ATOPOBIUM VAGINAE; BACTERIAL COLONIZATION; BEDTIME DOSAGE; CANDIDIASIS; CHLAMYDIASIS; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TREATMENT FAILURE; GARDNERELLA VAGINALIS; GASTROINTESTINAL SYMPTOM; GIARDIASIS; GRAM NEGATIVE BACTERIUM; HUMAN; INFECTION PREVENTION; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CRISPATUS; LACTOBACILLUS FERMENTUM; LACTOBACILLUS GASSERI; LACTOBACILLUS REUTERI; LACTOBACILLUS RHAMNOSUS; METALLIC TASTE; MIXED INFECTION; MORNING DOSAGE; MYCOSIS; NAUSEA; PATIENT COMPLIANCE; PH; POSTOPERATIVE INFECTION; PREMATURE LABOR; PROTOZOAL INFECTION; REINFECTION; REVIEW; SEXUALLY TRANSMITTED DISEASE; SIDE EFFECT; STREPTOCOCCUS THERMOPHILUS; SURGICAL ABORTION; TASTE; TRICHOMONIASIS; UROGENITAL TRACT INFECTION; VAGINA CANDIDIASIS; VAGINA DISCHARGE; VAGINA FLORA; VAGINITIS; VOMITING;

EID: 82855168761     PISSN: None     EISSN: 11791411     Source Type: Journal    
DOI: 10.2147/ijwh.s23814     Document Type: Review

References (92)

1. Koumans EH, Sternberg M, Bruce C, et al. The prevalence of bacterial vaginosis in the United States, 2001-2004; associations with symptoms, sexual behaviors, and reproductive health. Sex Transm Dis. 2007;34: 864-869.
2. Turovskiy Y, Sutyak Noll K, Chikindas ML. The aetiology of bacterial vaginosis. J Appl Microbiol. 2011;110:1105-1128.
3. Smart S, Singal A, Mindel A. Social and sexual risk factors for bacterial vaginosis. Sex Transm Infect. 2004;80:58-62.
4. Yotebieng M, Turner AN, Hoke TH, Van Damme K, Rasolofomanana JR, Behets F. Effect of consistent condom use on 6-month prevalence of bacterial vaginosis varies by baseline BV status. Trop Med Int Health. 2009;14:480-456.
5. Gray RH, Kigozi G, Serwadda D, et al. The effects of male circumcision on female partners' genital tract symptoms and vaginal infections in a randomized trial in Rakai, Uganda. Am J Obstet Gynecol. 2009;200: 42. e1-e7.
6. Gardner HL, Dukes CD. Haemophilus vaginalis vaginitis: a newly defned specifc infection previously classifed non-specifc vaginitis. Am J Obstet Gynecol. 1955;69:962-976.
7. Lamont R F, Sobel JD, Akins RA, et al. The vaginal microbiome: new information about genital tract fora using molecular based techniques. BJOG. 2011;118:533-549.
8. Fredricks DN, Fiedler TL, Marrazzo JM. Molecular identifcation of bacteria associated with bacterial vaginosis. N Engl J Med. 2005;353: 1899-1911.
9. Swidsinski A, Mendling W, Loening-Baucke V, et al. An adherent Gardnerella vaginalis bioflm persists on the vaginal epithelium after standard therapy with oral metronidazole. Am J Obstet Gynecol. 2008; 198:97. e1-e6.
10. Menard J P, Fenollar F, Henry M, Bretelle F, Raoult D. Molecular quantifcation of Gardnerella vaginalis and Atopobium vaginae loads to predict bacterial vaginosis. Clin Infect Dis. 2008;47:33-43.
11. Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecifc vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med. 1983;74:14-22.
12. Nugent R P, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol. 1991;29:297-301.
13. Brotman RM, Klebanoff MA, Nansel TR, et al. Bacterial vaginosis assessed by gram stain and diminished colonization resistance to incident gonococcal, chlamydial, and trichomonal genital infection. J Infect Dis. 2010;202:1907-1915.
14. Allsworth JE, Lewis VA, Peipert JF. Viral sexually transmitted infections and bacterial vaginosis: 2001-2004 National Health and Nutrition Examination Survey data. Sex Transm Dis. 2008;35: 791-796.
15. Larsson PG, Platz-Christensen JJ, Thejls H, Forsum U, Påhlson C. Incidence of pelvic infammatory disease after frst-trimester legal abortion in women with bacterial vaginosis after treatment with metronidazole: a double-blind, randomized study. Am J Obstet Gynecol. 1992;166:100-103.
16. Svare JA, Schmidt H, Hansen BB, Lose G. Bacterial vaginosis in a cohort of Danish pregnant women: prevalence and relationship with preterm delivery, low birthweight and perinatal infections. BJOG. 2006;113:1419-1425.
17. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (1998). Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegu-latoryInformation/Guidances/ucm070969.pdf. Accessed July 22, 2011.
18. Löfmark S, Edlund C, Nord CE. Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin Infect Dis. 2010; 50(Suppl 1):S16-S23.
19. Koumans EH, Markowitz LE, Hogan V; CDC BV Working Group. Indications for therapy and treatment recommendations for bacterial vaginosis in nonpregnant and pregnant women: a synthesis of data. Clin Infect Dis. 2002;35:S152-S172.
20. Oduyebo OO, Anorlu RI, Ogunsola FT. The effects of antimicrobial therapy on bacterial vaginosis in non-pregnant women. Cochrane Database Syst Rev. 2009;3:CD006055.
21. Hanson JM, McGregor JA, Hillier SL, et al. Metronidazole for bacterial vaginosis. A comparison of vaginal gel vs oral therapy. J Reprod Med. 2000;45:889-896.
22. Ransom SB, McComish JF, Greenberg R, Tolford DA. Oral metronidazole vs Metrogel Vaginal for treating bacterial vaginosis. Cost-effectiveness evaluation. J Reprod Med. 1999;44:359-362.
23. Lugo-Miro VI, Green M, Mazur L. Comparison of different metron-idazole therapeutic regimens for bacterial vaginosis. A meta-analysis. JAMA. 1992;268:92-95.
24. Joesoef MR, Schmid G P, Hillier SL. Bacterial vaginosis: review of treatment options and potential clinical indications for therapy. Clin Infect Dis. 1999;28 Suppl 1:S57-S65.
25. Schwebke JR, Desmond RA. A randomized trial of the duration of therapy with metronidazole plus or minus azithromycin for treatment of symptomatic bacterial vaginosis. Clin Infect Dis. 2007;44:213-219.
26. Brandt M, Abels C, May T, Lohmann K, Schmidts-Winkler I, Hoyme UB. Intravaginally applied metronidazole is as effective as orally applied in the treatment of bacterial vaginosis, but exhibits signifcantly less side effects. Eur J Obstet Gynecol Reprod Biol. 2008;141:158-162.
27. Mikamo H, Kawazoe K, Izumi K, Watanabe K, Ueno K, Tamaya T. Comparative study on vaginal or oral treatment of bacterial vaginosis. Chemotherapy. 1997;43:60-68.
28. Sobel J, Peipert J F, McGregor JA, et al. Effcacy of clindamycin vaginal ovule (3-day treatment) vs clindamycin vaginal cream (7-day treatment) in bacterial vaginosis. Infect Dis Obstet Gynecol. 2001;9:9-15.
29. Faro S, Skokos CK; Clindesse Investigators Group. The effcacy and safety of a single dose of Clindesse vaginal cream versus a seven-dose regimen of Cleocin vaginal cream in patients with bacterial vaginosis. Infect Dis Obstet Gynecol. 2005;13:155-160.
30. Ekgren J, Norling BK, Degre M, Midtvedt T. Comparison of tinidazole given as a single dose and on 2 consecutive days for the treatment of nonspecifc bacterial vaginosis. Gynecol Obstet Invest. 1988;26: 313-317.
31. Food and Drug Administration. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021618s003lbl.pdf. Accessed July 22, 2011.
32. Livengood CH, Ferris DG, Wiesenfeld HC, et al. Effectiveness of two tinidazole regimens in treatment of bacterial vaginosis: a randomized controlled trial. Obstet Gynecol. 2007;110:302-309.
33. Armstrong NR, Wilson JD. Tinidazole in the treatment of bacterial vaginosis. Int J Womens Health. 2010;1:59-65.
34. Schwebke JR, Desmond RA. Tinidazole vs metronidazole for the treatment of bacterial vaginosis. Am J Obstet Gynecol. 2011;204: 211. e1-e6.
35. Milani M, Barcellona E, Agnello A. Effcacy of the combination of 2 g oral tinidazole and acidic buffering vaginal gel in comparison with vaginal clindamycin alone in bacterial vaginosis: a randomized, investigator-blinded, controlled trial. Eur J Obstet Gynecol Reprod Biol. 2003;109:67-71.
36. Gillis JC, Wiseman LR. Secnidazole. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic use in the management of protozoal infections and bacterial vaginosis. Drugs. 1996;51:621-638.
37. Bohbot JM, Vicaut E, Fagnen D, Brauman M. Treatment of bacterial vaginosis: a multicenter, double-blind, double-dummy, randomised phase III study comparing secnidazole and metronidazole. Infect Dis Obstet Gynecol. 2010;2010. pii: 705-692.
38. Núñez JT, Gómez G. Low-dose secnidazole in the treatment of bacterial vaginosis. Int J Gynaecol Obstet. 2005;88:281-285.
39. Narayana RC, Harish NM, Gulzar AM, Prabhakara P, Singh AK, Subrahmanyam E V. Formulation and in vitro evaluation of in situ gels containing secnidazole for vaginitis. Yakugaku Zasshi. 2009;129: 569-574.
40. Food and Drug Administration, World Health Organization (2001). Available at: http://www.who.int/foodsafety/publications/fs_management/en/probiotics.pdf. Accessed July 22, 2011.
41. Howard JC, Heinemann C, Thatcher BJ, Martin B, Gan BS, Reid G. Identifcation of collagen-binding proteins in Lactobacillus spp. with surface-enhanced laser desorption/ionization-time of fight proteinchip technology. Appl Environ Microbiol. 2000;66:4396-4400.
42. Pascual LM, Daniele MB, Ruiz F, Giordano W, Pajaro C, Barberis L. Lactobacillus rhamnosus L60, a potential probiotic isolated from the human vagina. J Gen Appl Microbiol. 2008;54:141-148.
43. Sheil B, Shanahan F, O'Mahony L. Probiotic effects on infammatory bowel disease. J Nutr. 2007;137:819S-824S.
44. Reid G, Beuerman D, Heinemann C, Bruce AW. Probiotic Lactobacillus dose required to restore and maintain a normal vaginal fora. FEMS Immunol Med Microbiol. 2001;32:37-41.
45. Reid G, Charbonneau D, Erb J, et al. Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 signifcantly alters vaginal fora: randomized, placebo-controlled trial in 64 healthy women. FEMS Immunol Med Microbiol. 2003;35:131-134.
46. Hemmerling A, Harrison W, Schroeder A, et al. Phase 2a study assessing colonization effciency, safety, and acceptability of Lactobacillus crispatus CTV-05 in women with bacterial vaginosis. Sex Transm Dis. 2010;37:745-750.
47. Petricevic L, Witt A. The role of Lactobacillus casei rhamnosus Lcr 35 in restoring the normal vaginal fora after antibiotic treatment of bacterial vaginosis. BJOG. 2008;115:1369-1374.
48. Ruiz FO, Gerbaldo G, Asurmendi P, Pascual LM, Giordano W, Barberis IL. Antimicrobial activity, inhibition of urogenital pathogens, and synergistic interactions between lactobacillus strains. Curr Microbiol. 2009;59:497-501.
49. Senok AC, Verstraelen H, Temmerman M, Botta GA. Probiotics for the treatment of bacterial vaginosis. Cochrane Database Syst Rev. 2009;4: CD006289.
50. Falagas ME, Betsi GI, Athanasiou S. Probiotics for the treatment of women with bacterial vaginosis. Clin Microbiol Infect. 2007;13: 657-664.
51. Anukam KC, Osazuwa E, Osemene GI, Ehigiagbe F, Bruce AW, Reid G. Clinical study comparing probiotic Lactobacillus GR-1 and RC-14 with metronidazole vaginal gel to treat symptomatic bacterial vaginosis. Microbes Infect. 2006;8:2772-2776.
52. ®) on vaginitis and vaginosis with disrupted vaginal microfora: a multicenter, randomized, single-blind, active-controlled pilot study. Gynecol Obstet Invest. 2010;70: 264-272.
53. Anukam K, Osazuwa E, Ahonkhai I, et al. Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial. Microbes Infect. 2006;8:1450-1454.
54. Martinez RC, Franceschini SA, Patta MC, et al. Improved cure of bacterial vaginosis with single dose of tinidazole (2 g), Lactobacillus rhamnosus GR-1, and Lactobacillus reuteri RC-14: a randomized, double-blind, placebo-controlled trial. Can J Microbiol. 2009;55:133-138.
55. Hummelen R, Changalucha J, Butamanya NL, Cook A, Habbema JD, Reid G. Lactobacillus rhamnosus GR-1 and L. reuteri RC-14 to prevent or cure bacterial vaginosis among women with HIV. Int J Gynaecol Obstet. 2010;111:245-248.
56. Larsson PG, Stray-Pedersen B, Ryttig KR, Larsen S. Human lactobacilli as supplementation of clindamycin to patients with bacterial vaginosis reduce the recurrence rate; a 6-month, double-blind, randomized, placebo-controlled study. BMC Womens Health. 2008;8:3.
57. Marcone V, Rocca G, Lichtner M, Calzolari E. Long-term vaginal administration of Lactobacillus rhamnosus as a complementary approach to management of bacterial vaginosis. Int J Gynaecol Obstet. 2010;110:223-226.
58. Ya W, Reifer C, Miller LE. Effcacy of vaginal probiotic capsules for recurrent bacterial vaginosis: a double-blind, randomized, placebo-controlled study. Am J Obstet Gynecol. 2010;203:120. e1-e6.
59. Holley RL, Richter HE, Varner RE, Pair L, Schwebke JR. A randomized, double-blind clinical trial of vaginal acidifcation versus placebo for the treatment of symptomatic bacterial vaginosis. Sex Transm Dis. 2004;31:236-238.
60. Simoes JA, Bahamondes LG, Camargo R P, et al. A pilot clinical trial comparing an acid-buffering formulation (ACIDFORM gel) with metronidazole gel for the treatment of symptomatic bacterial vaginosis. Br J Clin Pharmacol. 2006;61:211-217.
61. Decena DC, Co JT, Manalastas RM, et al. Metronidazole with Lactacyd vaginal gel in bacterial vaginosis. J Obstet Gynaecol Res. 2006;32:243-251.
62. Shaaban OM, Fetih GN, Abdellah NH, Ismail S, Ibrahim MA, Ibrahim ES. Pilot randomized trial for treatment of bacterial vaginosis using in situ forming metronidazole vaginal gel. J Obstet Gynaecol Res. 2011;37:874-881.
63. Perioli L, Ambrogi V, Pagano C, Scuota S, Rossi C. FG90 chitosan as a new polymer for metronidazole mucoadhesive tablets for vaginal administration. Int J Pharm. 2009;377:120-127.
64. Dobaria N, Mashru R. Design and in vitro evaluation of a novel bioadhesive vaginal drug delivery system for clindamycin phosphate. Pharm Dev Technol. 2010;15:405-414.
65. Mendling W, Mailland F. Microbiological and pharmaco-toxicological profle of nifuratel and its favourable risk/beneft ratio for the treatment of vulvo-vaginal infections. A review. Arzneimittelforschung. 2002; 52:8-13.
66. Togni G, Battini V, Bulgheroni A, Mailland F, Caserini M, Mendling W. In vitro activity of nifuratel on vaginal bacteria: could it be a good candidate for the treatment of bacterial vaginosis? Antimicrob Agents Chemother. 2011;55:2490-2492.
67. Donders G, Bellen G, Ausma J, et al. The effect of antifungal treatment on the vaginal fora of women with vulvo-vaginal yeast infection with or without bacterial vaginosis. Eur J Clin Microbiol Infect Dis. 2011;30: 59-63.
68. Sanchez S, Garcia PJ, Thomas KK, Catlin M, Holmes KK. Intravaginal metronidazole gel versus metronidazole plus nystatin ovules for bacterial vaginosis: a randomized controlled trial. Am J Obstet Gynecol. 2004;191:1898-1906.
69. Braga PC, Dal Sasso M, Culici M, Spallino A. Inhibitory activity of thymol on native and mature Gardnerella vaginalis bioflms: in vitro study. Arzneimittelforschung. 2010;60:675-681.
70. Sosto F, Benvenuti C; CANVA Study Group. Controlled study on thymol + eugenol vaginal douche versus econazole in vaginal candidi-asis and metronidazole in bacterial vaginosis. Arzneimittelforschung. 2011;61:126-131.
71. Strandberg KL, Peterson ML, Lin YC, Pack MC, Chase DJ, Schlievert PM. Glycerol monolaurate inhibits Candida and Gardnerella vaginalis in vitro and in vivo but not Lactobacillus. Antimicrob Agents Chemother. 2010;54:597-601.
72. Novakov Mikic A, Budakov D. Comparison of local metronidazole and a local antiseptic in the treatment of bacterial vaginosis. Arch Gynecol Obstet. 2010;282:43-47.
73. Chen M, Pan X, Wu H, et al. Preparation and anti-bacterial properties of a temperature-sensitive gel containing silver nanoparticles. Pharmazie. 2011;66:272-277.
74. Rousseau V, Lepargneur J P, Roques C, Remaud-Simeon M, Paul F. Prebiotic effects of oligosaccharides on selected vaginal lactobacilli and pathogenic microorganisms. Anaerobe. 2005;11:145-153.
75. Zeng ZM, Liao Q P, Ya o C, et al. Directed shift of vaginal fora after topical application of sucrose gel in a phase III clinical trial: a novel treatment for bacterial vaginosis. Chin Med J. 2010;123:2051-2057.
76. US Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines 2010. Available at: http://www.cdc.gov/mmwr/pdf/rr/rr5912.pdf. Accessed July 22, 2011.
77. McDonald HM, Brocklehurst P, Gordon A. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev. 2007;1: CD000262.
78. Nygren P, Fu R, Freeman M, et al. Evidence on the benefts and harms of screening and treating pregnant women who are asymptomatic for bacterial vaginosis: an update review for the US Preventive Services Task Force. Ann Intern Med. 2008;148:220-233.
79. Achilles SL, Reeves MF; Society of Family Planning. Prevention of infection after induced abortion: release date October 2010: SFP guideline 20102.
80. Wawer MJ, Sewankambo NK, Serwadda D, et al. Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Rakai Project Study Group. Lancet. 1999;353: 525-535.
81. Grosskurth H, Mosha F, Todd J, et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet. 1995;346:530-536.
82. Moreira C, Venkatesh KK, DeLong A, et al. Effect of treatment of asymptomatic bacterial vaginosis on HIV-1 shedding in the genital tract among women on antiretroviral therapy: a pilot study. Clin Infect Dis. 2009;49:991-992.
83. Schwebke JR, Desmond R. A randomized trial of metronidazole in asymptomatic bacterial vaginosis to prevent the acquisition of sexually transmitted diseases. Am J Obstet Gynecol. 2007;196:517. e1-e6.
84. Bradshaw CS, Tabrizi SN, Fairley CK, Morton AN, Rudland E, Garland SM. The association of Atopobium vaginae and Gardnerella vaginalis with bacterial vaginosis and recurrence after oral metronida-zole therapy. J Infect Dis. 2006;194:828-836.
85. De Backer E, Verhelst R, Verstraelen H, et al. Antibiotic susceptibility of Atopobium vaginae. BMC Infect Dis. 2006;6:51.
86. Bradshaw CS, Morton AN, Hocking J. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis. 2006;193: 1478-1486.
87. Hay P. Recurrent bacterial vaginosis. Curr Opin Infect Dis. 2009;22: 82-86.
88. Klatt TE, Cole DC, Eastwood DC, Barnabei VM. Factors associated with recurrent bacterial vaginosis. J Reprod Med. 2010;55:55-61.
89. Bunge KE, Beigi RH, Meyn LA, Hillier SL. The effcacy of retreatment with the same medication for early treatment failure of bacterial vaginosis. Sex Transm Dis. 2009;36:711-713.
90. Reichman O, Akins R, Sobel JD. Boric acid addition to suppressive antimicrobial therapy for recurrent bacterial vaginosis. Sex Transm Dis. 2009;36:732-734.
91. Wilson JD, Shann SM, Brady SK, Mammen-Tobin AG, Evans AL, Lee RA. Recurrent bacterial vaginosis: the use of maintenance acidic vaginal gel following treatment. Int J STD AIDS. 2005;16:736-738.
92. MacPhee RA, Hummelen R, Bisanz JE, Miller WL, Reid G. Probiotic strategies for the treatment and prevention of bacterial vaginosis. Expert Opin Pharmacother. 2010;11:2985-2995.